18 August 2020 : Clinical Research
Effects of a Secondary Prevention Combination Therapy with beta-Blocker and Statin on Major Adverse Cardiovascular Events in Acute Coronary Syndrome Patients
Ling Zhu12ABCDEFG, Qianwei Cui1BCEF, Ying Liu3BCEF, Zhongwei Liu1BCE, Yong Zhang1BCF, Fuqiang Liu1ACDEFG, Junkui Wang1ACDEFG*DOI: 10.12659/MSM.925114
Med Sci Monit 2020; 26:e925114
Figure 1 The cumulative incidence of major adverse cardiovascular events (MACEs). Compared with no therapy group, the cumulative incidence of MACEs gradually decreased in the beta-blocker monotherapy group, statin monotherapy group, and cotherapy group (P<.001).